Pharmaceuticals News and Research

RSS

Micromet reports total revenues of $4.6M for three months ended December 31, 2009

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the fourth quarter and full year ended December 31, 2009. The Company also highlighted recent pipeline progress and outlined expected 2010 milestones.

4 Mar 2010

Cornerstone Therapeutics' fourth-quarter net revenues increase 48%

Cornerstone Therapeutics Inc. today reported financial results for the three and 12 months ended December 31, 2009.

4 Mar 2010

Celldex Therapeutics reports net loss of $13.5M for fourth-quarter of 2009

Celldex Therapeutics, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009. Celldex reported a net loss of $13.5 million, or $0.43 per share, for the fourth quarter of 2009 compared to a net loss of $7.5 million, or $0.47 per share, for the fourth quarter of 2008.

4 Mar 2010

Inspire Pharmaceuticals reports net loss of $2.6 million for 2009 fourth quarter

Inspire Pharmaceuticals, Inc. announced today financial results for the fourth quarter and year ended December 31, 2009, reporting a net loss of $2.6 million or ($0.03) per share for the fourth quarter and a net loss of $40.0 million or ($0.60) per share for the full year.

4 Mar 2010

Alnylam Pharmaceuticals asks Court to dismiss MIT from any claims for monetary damages in ongoing litigation

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the company and Max Planck have asked the Court to dismiss the Massachusetts Institute of Technology from any claims for monetary damages in the ongoing litigation related to the Tuschl I patent series.

4 Mar 2010

Atacama Labs and Excella partner to sell PDG Granule and Tablet Manufacturing Services

Atacama Labs Oy has developed an innovative oral drug delivery technology (called 'pneumatic dry granulation' or 'PDG Technology(TM)'). The technology is aimed to replace existing solid dosage form development and manufacturing methods (like wet granulation or standard roller compaction) and will help both NCE galenic developers and life cycle managers to overcome development or differentiation issues.

4 Mar 2010

Project ProSPECTus develops technology for next generation SPECT imaging to improve diagnosis of cancer

Time taken to detect brain tumours could soon be significantly reduced thanks to an ongoing pioneering project led by the University of Liverpool with the Nuclear Physics Group and Technology departments at the Science and Technology Facilities Council (STFC) at Daresbury Laboratory.

4 Mar 2010

Repligen acquires BioFlash

Repligen Corporation announced today that it has acquired the assets of BioFlash Partners, LLC, (BioFlash) including a technology platform for the production of pre-packed, "plug and play" chromatography columns. This patented technology enables economical production of chromatography columns in a format that is ready for use in the production of a broad range of biopharmaceuticals including monoclonal antibodies, vaccines and recombinant proteins.

4 Mar 2010

New chemical classes of preclinical compounds identified for Alzheimer’s disease

In an announcement today, Mount Sinai School of Medicine and Medisyn Technologies, Inc. said they have identified new chemical classes of preclinical compounds that may eventually lead to the first effective management of toxic amyloid aggregation and accumulation in the brain— an abnormal biological process long suspected by many researchers to be a major culprit in the onset and progression of Alzheimer’s disease.

4 Mar 2010

Hand sanitizers sold in Puerto Rico contain harmful bacteria, says FDA

The U.S. Food and Drug Administration is warning consumers in Puerto Rico that two hand sanitizers - "Bee-Shield Hand Sanitizer" with Aloe Vera (10 fl. oz. or 1 gallon bottles) and "MD Quality Hand Sanitizer" with Aloe Vera (10 fl oz. bottles) - contain high levels of a bacteria, Burkholderia cepacia, that can cause serious infections in humans.

4 Mar 2010

Zoraxel for treatment of ED: Rexahn Pharmaceuticals submits Phase IIb protocol to FDA

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase IIb protocol to the FDA for ZoraxelTM for the treatment of erectile dysfunction (ED).

4 Mar 2010

Covidien: Mallinckrodt launches Oral Transmucosal Fentanyl Citrate

Covidien, a leading global provider of healthcare products, today announced that Mallinckrodt Inc., a Covidien company, has launched its Oral Transmucosal Fentanyl Citrate (CII) to distributors serving retail pharmacies across the country.

3 Mar 2010

CPEX Pharmaceuticals' fourth-quarter 2009 revenues up 23%

CPEX Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009. For the quarter CPEX reported revenues of $5.2 million and a net loss of $498,000. For the year CPEX reported revenues of $18.7 million and a net loss of $3.0 million.

3 Mar 2010

Seattle Genetics generates $110M through ADC technology license agreements

Seattle Genetics, Inc. announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Genentech, Inc., a wholly owned member of the Roche Group.

3 Mar 2010

VUCCC files for patent protection: New treatment regimen for Type 1 insulin-dependent diabetes

VUCCC P/L is pleased to announce that it has filed for patent protection of its ground breaking new treatment regimen for Type 1 'insulin-dependent' diabetes, through the European Patent Office.

3 Mar 2010

YM BioSciences files Form 6K regarding certain nimotuzumab US patents

YM BioSciences Inc., announces that it filed a Form 6K describing that certain US patents for nimotuzumab licensed to YM's majority-owned Canadian subsidiary , CIMYM BioSciences Inc., have become subject to a lien in the United States, pursuant to a court order, to a third party.

3 Mar 2010

PCMA releases statement on GAO report that examines specialty-tier prescription drugs in Medicare Part D

“Meaningful biogenerics legislation should be the first stop for policymakers tasked with financing health reform. PCMA and a broad coalition of consumers, employers, labor unions, and others support bipartisan legislation that would create a regulatory pathway for the Food and Drug Administration to approve generic versions of biologic products.”

3 Mar 2010

Positive clinical trial results of EndoBarrier Gastrointestinal Liner device announced

GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced initial, positive results from a clinical trial evaluating 12 months of treatment with the EndoBarrier™ Gastrointestinal Liner.

3 Mar 2010

"Stem cells in drug discovery and development" workshop to be held during toxicology annual meeting

Cellular Dynamics International (CDI) and Hoffmann-La Roche Inc. (Roche) today announced a workshop to be held during the Society of Toxicology Annual Meeting in Salt Lake City, UT, on March 7 - 11.

3 Mar 2010

Genetic Immunity to present data on DermaVir for HIV/AIDS at DNA Vaccines 2010

Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine vaccines, will present data at this week’s DNA Vaccines 2010 in New Orleans, LA concerning the formulation and topical administration of the DermaVir therapeutic vaccine for HIV/AIDS. DNA Vaccine 2010 invites leading scientists to report on the latest research in the progressive field of DNA or Genetic Vaccines.

3 Mar 2010

Pharmaceuticals News and Research

Micromet reports total revenues of $4.6M for three months ended December 31, 2009

Cornerstone Therapeutics' fourth-quarter net revenues increase 48%

Celldex Therapeutics reports net loss of $13.5M for fourth-quarter of 2009

Inspire Pharmaceuticals reports net loss of $2.6 million for 2009 fourth quarter

Alnylam Pharmaceuticals asks Court to dismiss MIT from any claims for monetary damages in ongoing litigation

Atacama Labs and Excella partner to sell PDG Granule and Tablet Manufacturing Services

Project ProSPECTus develops technology for next generation SPECT imaging to improve diagnosis of cancer

Repligen acquires BioFlash

New chemical classes of preclinical compounds identified for Alzheimer’s disease

Hand sanitizers sold in Puerto Rico contain harmful bacteria, says FDA

Zoraxel for treatment of ED: Rexahn Pharmaceuticals submits Phase IIb protocol to FDA

Covidien: Mallinckrodt launches Oral Transmucosal Fentanyl Citrate

CPEX Pharmaceuticals' fourth-quarter 2009 revenues up 23%

Seattle Genetics generates $110M through ADC technology license agreements

VUCCC files for patent protection: New treatment regimen for Type 1 insulin-dependent diabetes

YM BioSciences files Form 6K regarding certain nimotuzumab US patents

PCMA releases statement on GAO report that examines specialty-tier prescription drugs in Medicare Part D

Positive clinical trial results of EndoBarrier Gastrointestinal Liner device announced

"Stem cells in drug discovery and development" workshop to be held during toxicology annual meeting

Genetic Immunity to present data on DermaVir for HIV/AIDS at DNA Vaccines 2010

Event guide: 3rd EHS for Biopharma Summit eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring